Vaxzevria (COVID-19 vaccine)

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:vaccine
gptkbp:age	adults 18 years and older
gptkbp:alsoKnownAs	gptkb:AZD1222 gptkb:Covishield
gptkbp:approvedBy	gptkb:World_Health_Organization gptkb:European_Medicines_Agency December 2020
gptkbp:category	gptkb:COVID-19_vaccines AstraZeneca products
gptkbp:contains	replication-deficient chimpanzee adenovirus vector SARS-CoV-2 spike protein genetic material
gptkbp:developedBy	gptkb:University_of_Oxford gptkb:AstraZeneca
gptkbp:dosingSchedule	two doses
gptkbp:emergencyServices	gptkb:European_Union gptkb:India gptkb:United_Kingdom
gptkbp:intervalBetweenDoses	4–12 weeks
gptkbp:manufacturer	gptkb:India gptkb:United_Kingdom gptkb:Serum_Institute_of_India
gptkbp:routeOfAdministration	intramuscular injection
gptkbp:sideEffect	fever fatigue headache rare blood clotting events
gptkbp:storage	2–8°C
gptkbp:target	gptkb:COVID-19
gptkbp:technology	gptkb:viral_vector_vaccine
gptkbp:WHOEmergencyUseListing	February 2021
gptkbp:bfsParent	gptkb:AstraZeneca_plc
gptkbp:bfsLayer	8
http://www.w3.org/2000/01/rdf-schema#label	Vaxzevria (COVID-19 vaccine)